The Commerce Department unveiled a $2B CHIPS‑funded quantum package that includes $1B for IBM’s new foundry and minority equity stakes in several startups.

NYC‑based Runway hit No. 45 on CNBC's Disruptor 50 after a $315M Series E and major product and compute moves that pushed its valuation toward $5.3B.

A new Frontiers study finds a small uptick in lung cancer incidence after COVID‑19, especially among current and former smokers, and points to the enzyme TYMP as a likely mechanism.

New York’s cannabis regulator has launched a pilot observational study testing oral THC and CBD for adults with inflammatory bowel disease, partnering with licensed dispensaries.

A PLOS ONE study traced a 2020 apartment outbreak to shared bathroom ducts and urges retrofits — exhaust fans and non‑return flaps — to reduce airborne spread.

Goldman Sachs' operations chief says the bank will build a 'digital factory floor' of AI agents to automate back‑office work while saying overall headcount should stay largely unchanged.

A Lancet‑published consensus has renamed PCOS to PMOS to emphasize hormonal and metabolic causes. Patient groups are split as the three‑year roll‑out begins.

Mounjaro's Q1 sales topped Keytruda, lifting Lilly's revenue and reshaping the blockbuster drug ranking.

Five major publishers and Scott Turow sued Meta in Manhattan, alleging millions of copyrighted books and articles were used to train Llama. The filing could reshape licensing and liability for AI training data.

The AP won a Pulitzer for a three‑year probe that traced surveillance tools from Silicon Valley to China and back into U.S. systems. The reporting raises fresh questions about oversight and tech policy.

Anthropic teamed with Blackstone, Hellman & Friedman and Goldman Sachs on a roughly $1.5B venture to put Claude into private‑equity and mid‑market companies.

New York City startups pulled in $1.6B in late-stage digital health funding in Q1 2026 as investors concentrate on AI-enabled, revenue-generating platforms.

MeiraGTx priced a roughly $100M share offering after reacquiring bota‑vec from Johnson & Johnson. The cash will fund regulatory filings and potential product launches.